A study of variables in gastrointestinal stromal tumor: surgical experience at a single institute


  • Udit Jaydeep Shah Department of General Surgery, GCS Medical College, Hospital and Research centre, Ahmedabad, Gujarat, India
  • Sushil D. Akruwala Department of General Surgery, GCS Medical College, Hospital and Research centre, Ahmedabad, Gujarat, India
  • Vidhyasagar M. Sharma Department of General Surgery, GCS Medical College, Hospital and Research centre, Ahmedabad, Gujarat, India
  • Manubhai V. Pipalia Department of General Surgery, GCS Medical College, Hospital and Research centre, Ahmedabad, Gujarat, India




GIST, Mesenchymal tumor, Cells of Cajal, Imatinib


Background: Gastrointestinal stromal tumors (GIST) have been recognized as a biologically distinctive tumor type, different from the smooth muscle and neural tumors of the gastrointestinal tract. They constitute majority of the gastrointestinal mesenchymal tumors of the gastrointestinal tract and are considered to be refractory to conventional chemotherapy or radiation. Surgery remains the mainstay of primary tumor management of GIST.

Methods: This was a cross sectional study of the diagnosis, management and clinical outcome of cases diagnosed with GIST of the gastrointestinal tract from a teaching institute in a single year and a comparison of findings with previously published cases.­­ Study included patients newly diagnosed with GIST and managed in department of general surgery from 10 April 2018 to 31 March 2019.

Results: Most patients were of age group 60-69 years with an almost equal incidence among males and females. Stomach and small bowel were found to be the commonest sites with an equal distribution of 45.45% with an average tumor size of 5 cms.

Conclusions: Surgical treatment remains the main stay of management for the GIST, depending on the location, staging and metastasis. Staging laparoscopy may be done to assess respectability as peritoneal deposits can be missed by CT scan. Immunohistochemistry is mandatory in defining GIST.


Kindblom LG, Remotti HE,Aldenborg Fand Meis-kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT). Gastrointestinal stromal tumors shows phenotypic characteristics of the interstitial cells of Cajal Am J Pathol. 1998;152:1259-69.

Judson I, Demetri G. Advances in the treatmentof gastrointestinal stromal tumours. Ann Oncol. 2007;18(Suppl 10):20–4.

Nishida T, Hirota S. Biological and clinicalreviewof stromal tumorsin the gastrointestinal tract. Histol Histopathol. 2000;15(4):1293-301.

Joensuu H. Gastrointestinal stromal tumor(GIST). Ann Oncol 2006;17(suppl 10):x280–6.

Ma GL, Murphy JD, Martinez ME, Sick lick JK. Epidemiology of Gastrointestinal stromal tumors in the era of histology codes: Results of a population-based study. Cancer Epidemiol Biomarkers Prev. 2015; 24(1):298–302.

Benesch M, Wardelmann E, Ferrari A, Brennan B, Verschuur A. Gastrointestinal stromal tumors (GIST) in children and adolescents: A comprehensive review of the current literature. Pediatr Blood Cancer. 2009;53(7):1171–9.

Fletcher CD, Berman JJ, Corless C. Diagnosis of gastrointestinal stromal tumors: a consensusapproach. Int J Surg Pathol. 2002;10(2):81–9.

Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteriaof gastrointestinal stromal tumors(GISTs): a review. Eur J Cancer. 2002;38(Suppl 5):S39–51.

Novelli M, Rossi S, Rodriguez-Justo M. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology. 2010;57(2):259–70.

Ando N, Goto H, Niwa Y. The diagnosis of GI stromal tumorswith EUS-guided fine needle aspirationwith immunohistochemical analysis. Gastrointest Endosc. 2002;55(1):37–43.

Sorour MA, Kassem MI, Ghazal AE. Gastrointestinal stromal tumors (GIST) related emergencies. Int J Surg. 2014;12(4):269-80.

Miettinen M, Lasota J, Review gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23(2):70-83.

Wang ZH, Liang XB, Wang Y, Ma GL, Qu YQ, Tian XW. Epidemiology survey of gastrointestinal stromal tumor in Shanxi Province in 2011. Zhonghua yi xue za zhi. 2013;93(32):2541-4.

Barakat FH, Haddad HA, Matalka II, Al-Orjani MS, Al-Masri MM, Sughayer MA. Characteristics of gastrointestinal stromal tumors in a Middle Eastern population. Saudi Med J. 2010;31(7):797-802.

Bokhary RY, Al-Maghrabi JA. Gastrointestinal stromal tumors in western Saudi Arabia. Saudi Med. J. 2010;31:437-41.

Saied GM, Kensarah AM. Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients. Int J Surg. 2010;8(2):105-8.

Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H. management of patients with gastrointestinal stromal tumor (GIST)–update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw. 2007;5(suppl 2):S1-29.

Desiderio J, Trastulli S, Cirocchi R, Boselli C, Noya G, Parisi A, Cavaliere D. Robotic gastric resection of large gastrointestinal stromal tumors. Int J Surg. 2013;11(2):191-6.






Original Research Articles